Gerber G S, Levine L A
Section of Urology, University of Chicago, Illinois.
J Urol. 1991 Sep;146(3):786-9. doi: 10.1016/s0022-5347(17)37921-1.
A total of 72 impotent patients entered into a pharmacological erection program using prostaglandin E1. Of the men 35 (49%) used prostaglandin E1 on a regular basis, while 37 (51%) failed to continue in the program beyond the in-office dose titration period. In patients who continue to use prostaglandin E1 the median duration of drug use is 7 months, with a range of 2 to 28 months. There have been no instances of cavernous fibrosis, systemic reaction or chemical priapism (erection present longer than 4 hours) in any patient. Only 8 men (11%) were unable to achieve an adequate erection with prostaglandin E1 injections. The most common adverse effect of prostaglandin E1 was penile pain after injection. The incidence of severe pain leading to drug discontinuation was 17% (12 of 72 patients) while mild to moderate pain occurred in 22% (16 of 72). Over-all, intracavernous prostaglandin E1 injections appear to be a safe, effective treatment for impotence in most men.
共有72名阳痿患者参与了使用前列腺素E1的药物勃起治疗方案。其中35名男性（49%）定期使用前列腺素E1，而37名男性（51%）在门诊剂量滴定期后未能继续参与该方案。在继续使用前列腺素E1的患者中，药物使用的中位持续时间为7个月，范围为2至28个月。所有患者均未出现海绵体纤维化、全身反应或化学性阴茎异常勃起（勃起持续超过4小时）的情况。只有8名男性（11%）在注射前列腺素E1后无法获得足够的勃起。前列腺素E1最常见的不良反应是注射后阴茎疼痛。导致停药的严重疼痛发生率为17%（72名患者中有12名），而轻度至中度疼痛发生率为22%（72名患者中有16名）。总体而言，海绵体内注射前列腺素E1似乎是大多数男性阳痿的一种安全、有效的治疗方法。
